Evidence map›Paper›PMID 26650568›Full record

ArticleEndocrinology2016

Ferredoxin 1b (Fdx1b) Is the Essential Mitochondrial Redox Partner for Cortisol Biosynthesis in Zebrafish.

Aliesha Griffin, Silvia Parajes, Meltem Weger, Andreas Zaucker, Angela E Taylor, Donna M O'Neil, Ferenc Müller, Nils Krone

Open access · hybridAbstract read
In one paragraph

Article in Endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Steroidogenic electron-transfer factors and their diseases.Annals of pediatric endocrinology & metabolism · 2021
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Aliesha GriffinCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Silvia ParajesCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Meltem WegerCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Andreas ZauckerCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Angela E TaylorCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Donna M O'NeilCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Ferenc MüllerCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Nils KroneCentre for Endocrinology, Diabetes, and Metabolism (A.G., S.P., M.W., A.Z., A.E.T., D.M.O., N.K.), School of Clinical and Experimental Medicine (F.M.), College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; and Department of Oncology and Metabolism (N.K.), University of Sheffield, Sheffield S10 2TG, United Kingdom.
Oxford Centre for Diabetes, Endocrinology and Metabolism · GBUniversity of Birmingham · GBUniversity of Sheffield · GB

Funding

Medical Research CouncilWellcome TrustWellcome Trust 16023-2012
6 · The paper itself

Abstract

Mitochondrial cytochrome P450 (CYP) enzymes rely on electron transfer from the redox partner ferredoxin 1 (FDX1) for catalytic activity. Key steps in steroidogenesis require mitochondrial CYP enzymes and FDX1. Over 30 ferredoxin mutations have been explored in vitro; however, no spontaneously occurring mutations have been identified in humans leaving the impact of FDX1 on steroidogenesis in the whole organism largely unknown. Zebrafish are an important model to study human steroidogenesis, because they have similar steroid products and endocrine tissues. This study aimed to characterize the influence of ferredoxin on steroidogenic capacity in vivo by using zebrafish. Zebrafish have duplicate ferredoxin paralogs: fdx1 and fdx1b. Although fdx1 was observed throughout development and in most tissues, fdx1b was expressed after development of the zebrafish interrenal gland (counterpart to the mammalian adrenal gland). Additionally, fdx1b was restricted to adult steroidogenic tissues, such as the interrenal, gonads, and brain, suggesting that fdx1b was interacting with steroidogenic CYP enzymes. By using transcription activator-like effector nucleases, we generated fdx1b mutant zebrafish lines. Larvae with genetic disruption of fdx1b were morphologically inconspicuous. However, steroid hormone analysis by liquid chromatography tandem mass spectrometry revealed fdx1b mutants failed to synthesize glucocorticoids. Additionally, these mutants had an up-regulation of the hypothalamus-pituitary-interrenal axis and showed altered dark-light adaptation, suggesting impaired cortisol signaling. Antisense morpholino knockdown confirmed Fdx1b is required for de novo cortisol biosynthesis. In summary, by using zebrafish, we generated a ferredoxin knockout model system, which demonstrates for the first time the impact of mitochondrial redox regulation on glucocorticoid biosynthesis in vivo.

Indexed as

AnimalsBrainChromatography, LiquidCytochrome P-450 Enzyme SystemFerredoxinsGene Expression Regulation, DevelopmentalGene Knockout TechniquesGlucocorticoidsGonadsHydrocortisoneIn Situ HybridizationInterrenal GlandLarvaMitochondriaOxidation-ReductionReal-Time Polymerase Chain ReactionCytochrome P-450 Enzyme SystemFerredoxinsGlucocorticoidsHydrocortisoneZebrafish Proteins

Identifiers

PMID26650568
PMCPMC4769370
OpenAlexW2192254949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.